- Home
- FTH vs SKYE Comparison
FTH vs SKYE Comparison
Compare FTH & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTH | SKYE |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9M | 27.1M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | FTH | SKYE |
|---|---|---|
| Price | $26.00 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 112.0K | ★ 176.0K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.50 | $0.57 |
| 52 Week High | $28.98 | $5.75 |
Technical Indicators
Market Signals| Indicator | FTH | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 38.16 |
| Support Level | N/A | $0.57 |
| Resistance Level | N/A | $0.84 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 1.50 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.